Therapeutic utility of Lung-MAP: ushering into an era of genomic and biomarker-driven clinical trials

被引：0
|
作者：
Zhang, Chenyue [1 ]
Wang, Haiyong [2 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Integrated Therapy, Shanghai, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Internal Med Oncol, Jinan, Peoples R China
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2021年 / 6卷 / 01期
关键词：
D O I：
10.1038/s41392-021-00557-9
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：3
相关论文
共 31 条
  • [1] Therapeutic utility of Lung-MAP: ushering into an era of genomic and biomarker-driven clinical trials
    Chenyue Zhang
    Haiyong Wang
    Signal Transduction and Targeted Therapy, 6
  • [2] Patient Knowledge and Expectations Related to Return of Genomic Results in the Lung-MAP (SWOG 1400) Biomarker-Driven Clinical Trial
    Roth, J.
    Trivedi, M.
    Gray, S.
    Patrick, D.
    Burke, W.
    Delaney, D.
    Watabayashi, K.
    Litwin, P.
    Shah, P.
    Crew, K.
    Yee, M.
    Redman, M.
    Papadimitrakopoulou, V.
    Kelly, K.
    Gandara, D.
    Hershman, D.
    Ramsey, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S224 - S225
  • [3] Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
    Redman, Mary W.
    Papadimitrakopoulou, Vassiliki A.
    Minichiello, Katherine
    Hirsch, Fred R.
    Mack, Philip C.
    Schwartz, Lawrence H.
    Vokes, Everett
    Ramalingam, Suresh
    Leighl, Natasha
    Bradley, Jeff
    Miao, Jieling
    Moon, James
    Highleyman, Louise
    Miwa, Crystal
    LeBlanc, Michael L.
    Malik, Shakun
    Miller, Vincent A.
    Sigal, Ellen, V
    Adam, Stacey
    Wholley, David
    Sigman, Caroline
    Smolich, Beverly
    Blanke, Charles D.
    Kelly, Karen
    Gandara, David R.
    Herbst, Roy S.
    LANCET ONCOLOGY, 2020, 21 (12): : 1589 - 1601
  • [4] Innovative Clinical Trials: The LUNG-MAP Study
    Steuer, C. E.
    Papadimitrakopoulou, V.
    Herbst, R. S.
    Redman, M. W.
    Hirsch, F. R.
    Mack, P. C.
    Ramalingam, S. S.
    Gandara, D. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (05) : 488 - 491
  • [5] Lung-MAP (SWOG S1400): A Biomarker-Driven Protocol Accelerating Development of Squamous Cell Lung Cancer Therapies
    Herbst, Roy S.
    ANNALS OF ONCOLOGY, 2015, 26 : 5 - 5
  • [6] Biomarker-driven patient selection for early clinical trials
    Dienstmann, Rodrigo
    Rodon, Jordi
    Tabernero, Josep
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (03) : 305 - 312
  • [7] STRATIFICATION AND PARTIAL ASCERTAINMENT OF BIOMARKER VALUE IN BIOMARKER-DRIVEN CLINICAL TRIALS
    Simon, Richard
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (05) : 1011 - 1021
  • [8] Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
    Herbst, Roy S.
    Gandara, David R.
    Hirsch, Fred R.
    Redman, Mary W.
    LeBlanc, Michael
    Mack, Philip C.
    Schwartz, Lawrence H.
    Vokes, Everett
    Ramalingam, Suresh S.
    Bradley, Jeffrey D.
    Sparks, Dana
    Zhou, Yang
    Miwa, Crystal
    Miller, Vincent A.
    Yelensky, Roman
    Li, Yali
    Allen, Jeff D.
    Sigal, Ellen V.
    Wholley, David
    Sigman, Caroline C.
    Blumenthal, Gideon M.
    Malik, Shakun
    Kelloff, Gary J.
    Abrams, Jeffrey S.
    Blanke, Charles D.
    Papadimitrakopoulou, Vassiliki A.
    CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1514 - 1524
  • [9] From drug discovery to biomarker-driven clinical trials in lymphoma
    Younes, Anas
    Berry, Donald A.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (11) : 643 - 653
  • [10] From drug discovery to biomarker-driven clinical trials in lymphoma
    Anas Younes
    Donald A. Berry
    Nature Reviews Clinical Oncology, 2012, 9 : 643 - 653
1234